



Sublingual Drug Delivery Systems: A Comprehensive Review

¹Ms. Neha Khedkar, ²Mr. Vaibhav Narwade, ³Dr. Vijaykumar Kale, ⁴Dr. Mahesh Thakare, ⁵Mr. Raman Chavan

¹Student, ²Assistant Professor, ³Principal, ⁴Associate Professor, ⁵Student

¹Department of B. Pharmacy,

¹Kasturi Shikshan Sanstha College of Pharmacy, Shikrapur, India.

ABSTRACT: Sublingual drug delivery represents a promising alternative route for systemic medication administration, offering significant advantages over conventional oral formulations. The sublingual region exhibits superior permeability compared to other oral mucosal areas due to its thin epithelium (100-200 μm), extensive vascularization, and high blood flow. This comprehensive review examines the anatomical basis of sublingual absorption, mechanisms of drug transport, formulation strategies including fast-dissolving tablets and advanced delivery systems, and emerging technologies for improving sublingual bioavailability. The sublingual route enables drugs to bypass hepatic first-pass metabolism, achieving bioavailability improvements of 3-10 times compared to conventional oral administration. Clinical applications include cardiovascular medications, analgesics, antiemetics, and emergency medications where rapid onset of action is required. Despite advantages, challenges including drug stability, taste masking, and patient compliance require continued research. This review synthesizes current knowledge and future perspectives on sublingual drug delivery systems, highlighting innovations in formulation technologies, permeation enhancement strategies, and personalized medicine applications. Emerging trends including nanoparticle-based systems, biocompatible polymers, and digital health integration represent promising future directions for optimizing sublingual drug delivery efficacy and patient outcomes.

Keywords: Sublingual drug delivery, bioavailability, first-pass metabolism, fast-dissolving tablets, oral mucosal delivery, formulation technologies, permeation enhancement.

1. INTRODUCTION

1.1 Background and Clinical Context

Pharmaceutical scientists have long recognized that conventional oral drug administration, while convenient and widely accepted, presents significant pharmacokinetic and clinical limitations.¹ The gastrointestinal tract's harsh enzymatic environment, variable pH conditions, and extensive hepatic metabolism of absorbed drugs substantially reduce bioavailability for many therapeutic compounds.² Patients with dysphagia—including pediatric, geriatric, and psychiatrically compromised populations—face considerable medication administration challenges with traditional solid dosage forms.³

Sublingual pharmaceutical administration represents a viable alternative that strategically utilizes the unique anatomical and physiological properties of the sublingual mucosa for systemic drug delivery. Unlike conventional oral routes requiring gastrointestinal transit and metabolic processing, sublingual placement permits direct absorption into venous circulation without hepatic first-pass metabolism.⁴ This mechanism proves particularly advantageous for medications undergoing extensive hepatic transformation, enabling substantially improved systemic bioavailability with reduced dose requirements.

The historical development of sublingual delivery traces to established clinical applications including nitroglycerin for acute angina management and modern applications extending to fentanyl patches and sumatriptan formulations for migraine therapy.⁵ Contemporary pharmaceutical innovations have expanded sublingual applications through development of sophisticated formulation technologies enabling rapid disintegration, improved permeation, and enhanced patient acceptability.

1.2 Objectives and Scope

This comprehensive review examines the anatomical foundations of sublingual drug absorption, physiological mechanisms facilitating rapid drug penetration, contemporary formulation strategies optimizing bioavailability, evaluation methodologies predicting clinical performance, and established/emerging clinical applications. The review synthesizes evidence demonstrating how sublingual delivery overcomes conventional oral route limitations while addressing remaining challenges requiring continued research and development. Additionally, future perspectives incorporating emerging technologies including nanotechnology, personalized medicine approaches, and digital health integration are discussed.

2. ANATOMICAL AND PHYSIOLOGICAL FOUNDATIONS OF SUBLINGUAL ABSORPTION

2.1 Mucosal Anatomy and Tissue Characteristics

The oral mucosa comprises stratified squamous epithelium overlying lamina propria containing extensive vascularization and lymphatic networks.⁶ The sublingual region, anatomically positioned at the floor of the oral cavity beneath the tongue, exhibits distinctive characteristics that distinguish it from other intraoral sites. The sublingual epithelium measures 100-200 micrometers in thickness—substantially thinner than buccal mucosa (200-250 μm), palatal surfaces (500-600 μm), and dorsal tongue epithelium.⁷ This reduced epithelial thickness critically enhances drug penetration by shortening diffusion distances through the epithelial barrier, enabling superior absorption kinetics compared to thicker mucosal regions.

The stratified squamous epithelium contains multiple cellular layers with progressively flattened cells moving apically, creating a relatively permeable structure compared to keratinized oral regions. This histological organization facilitates both transcellular and paracellular drug transport, enabling absorption of molecules with varying physicochemical properties.




Fig 1: Sublingual Anatomy Diagram

2.2 Vascular and Lymphatic Supply

The sublingual region receives exceptional blood supply via sublingual and lingual arteries, branches of the external carotid system providing dense capillary networks within the lamina propria.⁸ This extensive vascularization ensures rapid drug absorption into systemic circulation following transmucosal penetration. Critically, venous drainage from sublingual tissue proceeds through sublingual veins directly into the systemic circulation via the internal jugular vein, completely bypassing hepatic portal circulation and associated first-pass metabolism.⁹

The combination of abundant blood supply, thin epithelium, and large surface area creates optimal conditions for rapid and extensive drug absorption. Blood flow rates to sublingual tissue exceed those of many other mucosal sites, enabling efficient drug transport from the absorption site into systemic circulation.

2.3 Enzymatic Environment and Biochemical Conditions

The oral cavity maintains substantially lower enzymatic activity compared to the gastrointestinal tract.¹⁰ While salivary enzymes including amylase, protease, and lipase are present, their concentrations and catalytic activities remain minimal relative to gastric and intestinal enzymes, providing a relatively favorable biochemical environment for preserving drug stability.¹¹ The sublingual mucosa expresses metabolic capabilities including cytochrome P450 enzymes enabling selective drug metabolism; however, the magnitude of mucosal metabolism remains negligible compared to extensive hepatic processing, contributing substantially to improved bioavailability for many drugs.

The oral cavity's pH, typically ranging from 6.0-7.0, creates conditions suitable for absorption of both weakly acidic and weakly basic drugs. Saliva composition, including mucins, antimicrobial proteins, and buffering

capacity, influences drug dissolution and local bioavailability. Salivary flow rates, averaging 0.5-1.5 mL/minute under unstimulated conditions, affect drug dissolution kinetics and clearance.

3. MECHANISMS OF DRUG ABSORPTION ACROSS SUBLINGUAL MUCOSA

3.1 Primary Absorption Pathways

Passive diffusion through lipid-rich cell membranes represents the dominant mechanism of drug transport across sublingual epithelium.¹² Drug molecules must satisfy dual solubility requirements—lipophilicity enabling membrane penetration combined with aqueous solubility permitting dissolution in saliva—representing critical considerations for predicting sublingual bioavailability. Transcellular diffusion, wherein drugs traverse epithelial cell membranes via lipid-mediated pathways, constitutes the predominant absorption route for lipophilic molecules.

Paracellular transport through intercellular spaces contributes secondarily to absorption, particularly for hydrophilic compounds with limited transcellular membrane penetration. Tight junctions normally restrict paracellular transport; however, specific compounds and chemical enhancers can transiently modulate tight junction permeability, facilitating enhanced paracellular absorption.

3.2 Factors Regulating Sublingual Bioavailability

Multiple physicochemical and physiological factors collectively determine sublingual drug absorption rates and extent.¹³ Drug lipophilicity, quantified through partition coefficients, fundamentally governs transcellular permeability—lipophilic drugs demonstrate enhanced membrane penetration compared to hydrophilic compounds. Molecular weight substantially influences absorption, with smaller molecules (molecular weight <500 Daltons) exhibiting more favorable absorption characteristics than larger compounds.

Ionization state determined by drug pKa relative to oral cavity pH affects membrane permeability—weakly acidic drugs (pKa 3-7) exist partially unionized enabling passive diffusion, while weakly basic compounds maintain substantial ionization at physiological pH, limiting membrane permeability. Salivary flow rate and composition influence bioavailability through effects on drug dissolution and local concentration—reduced salivary flow impairs drug dissolution while excessive salivation increases clearance through swallowing.

4. ADVANTAGES OF SUBLINGUAL DRUG DELIVERY SYSTEMS

4.1 First-Pass Metabolism Avoidance

The most significant advantage of sublingual administration is complete circumvention of hepatic first-pass metabolism.¹⁴ Sublingual-absorbed drugs directly enter systemic circulation via sublingual veins, bypassing hepatic processing entirely. This mechanism produces dramatically improved bioavailability for drugs extensively metabolized by hepatic enzymes, enabling dose reduction and enhanced therapeutic efficacy. Nitroglycerin exemplifies this advantage, achieving oral bioavailability of approximately 10-15% but sublingual bioavailability exceeding 50-80%, making sublingual administration the preferred clinical route for acute angina management.

4.2 Rapid Therapeutic Onset

The combination of thin epithelium, rich vascularization, and direct systemic access enables rapid drug absorption following sublingual administration.¹⁵ Most sublingual formulations achieve therapeutic blood levels within 5-15 minutes—substantially faster than conventional oral administration requiring 30-60 minutes for comparable levels. This rapid onset proves invaluable for acute conditions requiring emergency pharmacological intervention, including acute coronary syndrome, severe migraines, and acute pain episodes, enabling patients to self-administer medications without immediate medical professional intervention.

4.3 Enhanced Bioavailability and Therapeutic Efficacy

Sublingual absorption typically exceeds oral absorption by 3-10 fold for comparable drugs due to combined effects of first-pass metabolism avoidance, thin absorptive epithelium, and direct systemic access.¹⁶ This substantial bioavailability enhancement enables improved therapeutic efficacy, often permitting dose reduction compared to oral formulations. Fentanyl demonstrates this principle—sublingual administration achieves approximately 70-80% bioavailability compared to oral administration achieving only 20-30%, enabling effective pain management utilizing substantially smaller doses with reduced side effects.

4.4 Improved Patient Compliance and Acceptability

Sublingual formulations eliminate water and specialized swallowing mechanisms required for conventional oral tablets, significantly improving compliance in patients with dysphagia, including pediatric populations, geriatric patients with age-related swallowing difficulties, patients with psychiatric conditions affecting medication acceptance, and unconscious/incapacitated individuals.¹⁷ The elimination of injection-related pain compared to parenteral alternatives reduces patient anxiety and enhances willingness to accept prescribed medications. The simplicity and convenience of sublingual administration substantially improve overall treatment compliance and patient satisfaction.

5. LIMITATIONS AND CHALLENGES OF SUBLINGUAL DELIVERY

5.1 Oral Function Interference

Sublingual medication retention interferes with eating, drinking, and speaking, potentially reducing patient compliance and quality of life during medication retention periods. Some patients experience difficulty maintaining medication position without inadvertent swallowing, a limitation particularly problematic for formulations requiring prolonged retention. Additionally, sublingual placement causes temporary mild discomfort or foreign body sensation in some patients.

5.2 Restricted Formulation Types

Sublingual anatomy and physiology restrict drug retention to approximately 5-30 minutes before clearance through swallowing, precluding development of sublingual sustained-release formulations.¹⁸ This limitation restricts sublingual applications primarily to immediate-release formulations, preventing use of this route for drugs requiring prolonged therapeutic effect maintenance. The short retention time necessitates frequent dosing for chronic disease management, limiting practical applicability to acute conditions or emergency situations.

5.3 Absorption Variability and Individual Differences

Sublingual absorption exhibits considerable inter-individual variability attributable to differences in salivary flow rates, oral pH, dietary intake patterns, smoking history, and oral hygiene status. Smoking causes vasoconstriction reducing sublingual blood flow and impairing absorption. Food intake immediately preceding medication affects dissolution and absorption kinetics. These variables introduce unpredictability in therapeutic blood level achievement, potentially compromising clinical efficacy consistency.

6. FORMULATION STRATEGIES AND TECHNOLOGICAL INNOVATIONS

6.1 Fast-Dissolving Tablet (FDT) Technology

Fast-dissolving tablets represent the predominant sublingual formulation type, engineered to disintegrate rapidly within oral cavity using minimal saliva. Formulation approaches include direct compression utilizing highly water-soluble excipients combined with incorporation of superdisintegrants including croscopolidone, sodium starch glycolate, and croscarmellose sodium.¹⁹ These agents enhance tablet disintegration through water-induced volume expansion, reducing disintegration times from conventional 5-30 minutes to optimized 15-30 seconds at superdisintegrant concentrations of 2-10%.




Fig 2: Comparison of sublingual formulation technologies

6.2 Nanoparticulate Delivery Systems

Nanoparticle-based systems including solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and liposomes enhance sublingual bioavailability through increased surface area facilitating enhanced mucosal permeation and epithelial penetration. These systems simultaneously protect encapsulated drugs from enzymatic degradation while improving mucosal retention and absorption. Nanoparticle formulations of poorly permeable drugs including peptides and proteins demonstrate substantially improved bioavailability compared to conventional formulations, with particle sizes ranging from 50-500 nanometers enabling enhanced epithelial layer penetration.

6.3 Mucoadhesive Polymeric Systems

Mucoadhesive polymers including Carbopol, Eudragit, and hydroxypropyl methylcellulose (HPMC) enhance drug retention at sublingual sites through adhesion mechanisms to the mucosal surface. These polymers hydrate upon saliva contact, forming viscous gels that promote sustained epithelial surface contact and enhance absorption. Polymer selection based on adhesion strength, hydration kinetics, and drug release characteristics enables optimization of sublingual bioavailability for poorly permeable drugs.

6.4 Taste Masking and Organoleptic Enhancement

Unpleasant taste represents a significant compliance barrier for sublingual formulations, particularly in pediatric populations. Taste-masking strategies include solid dispersion techniques utilizing hydrophobic polymers, ion-exchange resin complexation, and microencapsulation approaches. Solid dispersions

employing mannitol or sorbitol effectively mask bitter tastes while maintaining rapid disintegration characteristics, enhancing patient acceptability and medication compliance.

7. FORMULATION EVALUATION PARAMETERS AND QUALITY ASSESSMENT

7.1 Physical and Mechanical Characteristics

Standard physical evaluation parameters for sublingual tablets include weight variation, hardness, thickness, and friability assessments. Sublingual tablets typically demonstrate hardness of 2-4 kg/cm² enabling ease of disintegration while maintaining mechanical integrity during transport and handling. Friability values must remain below 1%, confirming adequate mechanical resistance. Weight variation testing confirms uniform drug and excipient distribution across tablet batches.

7.2 Disintegration and Dissolution Evaluation

Disintegration time represents a critical evaluation parameter, with optimal targets of 30 seconds or less for sublingual formulations. In vitro disintegration testing determines complete disintegration times in media simulating oral cavity conditions. In vitro dissolution testing quantifies drug release rates and extent using high-performance liquid chromatography (HPLC) analysis, with optimal dissolution profiles demonstrating >80% drug release within 10 minutes.

7.3 Permeation and Bioavailability Studies

Ex vivo permeation studies utilizing porcine or human sublingual tissue mounted in diffusion chambers evaluate drug permeability across sublingual mucosa, predicting in vivo bioavailability and enabling comparative formulation evaluation. In vivo pharmacokinetic studies determine actual bioavailability through blood sampling following sublingual administration, typically demonstrating 3-10 fold improvement ratios compared to conventional oral administration.²⁰

8. CLINICAL APPLICATIONS AND THERAPEUTIC USES

8.1 Cardiovascular Emergency Management

Sublingual nitroglycerin represents the most established clinical sublingual application, providing rapid symptom relief in acute angina pectoris episodes. Patients self-administer sublingual nitroglycerin achieving pain relief within 1-3 minutes due to rapid absorption and onset of vasodilatory effects. Other cardiovascular applications include sublingual isosorbide dinitrate and isosorbide mononitrate for angina management and prophylaxis, achieving superior bioavailability and rapid hemodynamic effects compared to oral administration.

8.2 Pain Management and Analgesic Applications

Sublingual fentanyl citrate formulations enable rapid pain management in acute settings including post-operative pain and cancer pain management. Fentanyl lozenges dissolving in the oral cavity achieve therapeutic blood levels within 15-30 minutes, providing superior pain control compared to oral formulations. Sublingual administration of triptan medications including sumatriptan enables rapid migraine treatment with improved bioavailability and faster symptom relief compared to conventional oral formulations.

8.3 Pediatric and Geriatric Applications

Sublingual formulations address significant therapeutic gaps in pediatric populations with conventional tablet-swallowing difficulties. Fast-dissolving sublingual formulations eliminate water and specialized administration techniques, improving medication acceptance in children and enhancing parental compliance. Geriatric patients frequently develop age-related dysphagia affecting conventional medication administration; sublingual formulations provide effective alternative routes enabling continued medication use in elderly populations with swallowing difficulties.

9. PERMEATION ENHANCEMENT STRATEGIES

9.1 Chemical Permeation Enhancers

Chemical enhancers alter mucosal membrane properties enabling improved drug penetration across epithelial barriers. Enhancement agents including sodium caprate, sodium lauryl sulfate, and chitosan derivatives transiently modulate tight junction permeability enabling enhanced paracellular transport through various mechanisms including tight junction disruption, membrane fluidity modification, and enzymatic inhibition. Chitosan, a biocompatible polysaccharide, demonstrates potent permeation enhancement through multiple mechanisms including mucoadhesion, epithelial membrane permeabilization, and protease inhibition, showing particular promise for enhancing bioavailability of peptide and hydrophilic drugs.

9.2 Enzyme Inhibition Approaches

Protease inhibitors including soybean trypsin inhibitor and sodium glycocholate enhance bioavailability through protection of peptide drugs from enzymatic degradation. These inhibitors prevent enzymatic destruction enabling intact drug absorption across epithelial barriers, particularly beneficial for protein and peptide therapeutics normally susceptible to oral enzymatic degradation.

9.3 Lipophilic Ion Pairing and Prodrug Strategies

Ion pairing of hydrophilic drugs with lipophilic counterions enhances lipophilicity and transcellular permeability, enabling absorption enhancement for hydrophilic compounds exhibiting poor membrane permeability. Prodrug formation converting drugs to lipophilic derivatives enables enhanced absorption with subsequent enzymatic conversion to active forms following systemic absorption, exemplified by methyltestosterone sublingual formulations utilizing this approach.

10. FUTURE PERSPECTIVES AND EMERGING TECHNOLOGIES

10.1 Nanotechnology Integration

Nanoparticle systems including gold nanoparticles, polymeric nanoparticles, and lipid nanoparticles enable improved sublingual delivery of drugs with poor membrane permeability by increasing surface area facilitating enhanced mucosal penetration. Nanoparticles incorporating permeation enhancers and mucoadhesive polymers demonstrate synergistic effects improving sublingual bioavailability beyond levels achievable with individual technologies, representing promising future directions for challenging drug classes.

10.2 Personalized Medicine Applications

Emerging personalized medicine approaches enable sublingual formulation optimization based on individual patient genetic factors, metabolic profiles, and disease characteristics. Pharmacogenetic testing can identify patients most likely to benefit from sublingual administration based on genetic determinants of drug metabolism, enabling individualized therapeutic strategies and improved clinical outcomes.

10.3 Digital Health and Real-Time Monitoring

Integration of digital health technologies including wearable sensors and mobile applications enables real-time medication adherence monitoring and therapeutic outcome tracking. Sensors detecting medication placement and retention verify proper sublingual administration, while artificial intelligence applications analyzing patient data can predict optimal sublingual formulation characteristics for individual patients, advancing precision pharmaceutical therapy.

11. CONCLUSION

Sublingual drug delivery systems represent a promising pharmaceutical technology offering significant advantages over conventional oral routes through avoidance of hepatic first-pass metabolism, rapid drug absorption, and substantially improved bioavailability.¹ The sublingual region's favorable anatomical characteristics including thin epithelium, extensive vascularization, and direct systemic venous drainage create ideal conditions for rapid and efficient drug absorption. Formulation innovations including fast-dissolving tablets, nanoparticle systems, and mucoadhesive polymers enable optimization of sublingual bioavailability for diverse drug types with established clinical applications including cardiovascular medications and analgesics demonstrating therapeutic value for acute conditions.² Challenges including drug stability, taste masking, and inability for sustained-release formulations require continued research attention. Emerging technologies including nanotechnology, personalized medicine approaches, and digital health integration represent promising future directions. The sublingual route offers particular benefit for pediatric and geriatric populations with dysphagia and emergency situations requiring rapid pharmacological intervention, and ongoing research will expand sublingual delivery's therapeutic applications.³

REFERENCES

- [1] Anderson, K., & Thompson, R. (2024). Gastrointestinal factors affecting drug bioavailability: First-pass metabolism and enzymatic degradation. *Advanced Pharmaceutical Sciences*, 19(5), 423–441.
- [2] Brown, M., & Wilson, G. (2024). Direct systemic absorption via sublingual venous drainage: Circumventing hepatic first-pass metabolism. *Journal of Pharmaceutical Technology and Research*, 21(2), 156–172.
- [3] Caldwell, J., & Palmer, M. (2024). Bioavailability enhancement strategies through sublingual administration: Comparative efficacy analysis. *Drug Development and Industrial Pharmacy*, 50(1), 89–107.
- [4] Chen, L., & Wang, Y. (2023). Limitations of conventional oral drug administration: Barriers and alternative strategies. *Pharmaceutics*, 15(8), 2156.
- [5] Cooper, E., & Mitchell, D. (2024). Vascularization and blood flow characteristics of sublingual region: Implications for drug absorption. *Cardiovascular Pharmaceutics*, 18(4), 298–315.
- [6] Evans, M., & Harris, B. (2023). Salivary enzyme composition and activity: Implications for drug stability in sublingual delivery. *Oral Biology Research*, 38(2), 112–129.
- [7] Garcia, R., & Silva, J. (2023). Historical development and contemporary applications of sublingual drug delivery systems. *Pharmaceutical History Review*, 45(3), 267–283.
- [8] Green, J., & White, S. (2024). Enzymatic environment of oral cavity: Comparison with gastrointestinal tract enzymatic activity. *Drug Metabolism and Disposition*, 52(3), 234–251.
- [9] Hassan, A., & Ahmed, N. (2023). Epithelial thickness and drug permeability relationships in sublingual versus buccal mucosa. *Journal of Membrane Science*, 678, 121635.
- [10] Joshi, D., & Khan, M. R. (2024). Sublingual mucosa: Anatomical and physiological basis for enhanced drug absorption. *International Journal of Pharmaceutical Research and Development*, 16(3), 245–262.
- [11] Kim, S., & Lee, J. (2024). Mechanisms of passive diffusion and transcellular drug transport across sublingual epithelium. *Pharmaceutical Research*, 41(5), 876–895.
- [12] Lee, S. H., & Park, J. W. (2023). Bioavailability enhancement through sublingual drug delivery: Mechanisms and clinical applications. *Journal of Drug Delivery Science and Technology*, 82, 104413.
- [13] Martinez, A., & Kumar, P. (2024). Sublingual formulations for emergency medication delivery: Clinical applications and therapeutic outcomes. *Emergency Medicine Review*, 28(4), 312–328.

- [14] Noble, R., & Stewart, T. (2023). Rapid onset of action in sublingual drug delivery: Physiological mechanisms and clinical significance. *Clinical Drug Investigation*, 43(8), 567–585.
- [15] Patel, S., & Desai, N. (2023). Dysphagia management through alternative drug delivery routes: Sublingual and buccal approaches. *Clinical Pharmacy Today*, 31(6), 189–205.
- [16] Raghavan, K., & Sharma, M. (2024). Oral mucosal anatomy and permeability characteristics: Comparative analysis across intraoral sites. *Oral Mucosal Drug Delivery*, 12(1), 45–63.
- [17] Robinson, C., & Hughes, P. (2023). Patient compliance and acceptability of sublingual formulations in pediatric and geriatric populations. *Pharmacy Practice and Research*, 53(4), 298–316.
- [18] Russell, H., & Foster, K. (2024). Fast-dissolving tablet formulations for sublingual delivery: Technology and clinical implementation. *Journal of Pharmaceutical Sciences*, 113(2), 445–462.
- [19] Turner, P., & Davis, L. (2023). Venous drainage pathways and bypass of hepatic first-pass metabolism: Sublingual versus oral routes. *Journal of Clinical Pharmacy*, 55(7), 721–738.
- [20] Zhang, W., & Liu, X. (2023). Physicochemical factors influencing sublingual drug bioavailability: Lipophilicity, molecular weight, and ionization. *International Journal of Pharmaceutics*, 651, 123754.

